Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (NYSE: DHR) reported second quarter 2026 net earnings of $870 million, or $1.23 per diluted share, up 60% year-over-year. Non-GAAP adjusted diluted EPS rose 8% to $1.94. Revenue grew 5.5% to $6.3 billion, with non-GAAP core revenue up 3.0% and 4.5% excluding respiratory testing.
Operating cash flow was $1.5 billion and non-GAAP free cash flow $1.3 billion. Management cited a strong quarter in Life Sciences and mid-teens growth in bioprocessing orders, despite project timing effects on bioprocessing revenue. Danaher completed its Masimo acquisition earlier than anticipated and raised full-year 2026 adjusted EPS guidance to $8.45–$8.60, with expected non-GAAP core revenue growth of 3–4%.
Danaher (NYSE: DHR), through its operating company Leica Biosystems, has agreed to acquire StatLab Medical Products from private equity owners Audax Private Equity and Linden Capital Partners. The sale agreement is subject to customary closing conditions, and financial terms were not disclosed.
StatLab, founded in 1976 and headquartered in McKinney, Texas, manufactures pre-analytical products that support the full anatomic pathology workflow for pathology, histology, cytology and molecular diagnostics laboratories, as well as OEM customers, across the United States and Europe. Under Audax and Linden’s ownership, StatLab expanded from a primarily U.S.-focused supplier into a global integrated manufacturer, enhanced in-house production, built a dual-continent manufacturing footprint and completed nine strategic acquisitions to broaden its self-manufacturing capabilities. Linden reports approximately $14.0 billion of regulatory assets under management, while Audax Private Equity reports about $19.5 billion of assets under management as of January 2026.
The Danaher Foundation, supported by Danaher (NYSE:DHR), committed $1 million to support Ebola Bundibugyo outbreak response in the DRC and Uganda. Funds go to Save the Children, IRC and World Food Program USA for infection prevention, community health and food assistance.
Danaher (NYSE:DHR) will host its second quarter 2026 earnings conference call on July 21, 2026, starting at 8:00 a.m. ET for about one hour.
The call, slide presentation, replay, and earnings materials will be available in the website’s Investors section.
Masimo, a Danaher company (NYSE:DHR), received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression (OIRD) detection feature on the Radius VSM wearable monitor.
Powered by the smartSET pulse oximetry platform, it analyzes continuous physiologic data and issues escalating visual alarms to help clinicians identify respiratory risk earlier in hospital patients on opioid therapy.
Danaher (NYSE:DHR) has completed its acquisition of Masimo, a specialty diagnostics provider focused on pulse oximetry and AI-enabled patient monitoring. Masimo becomes a wholly-owned subsidiary, will operate as a stand-alone company within Danaher’s Diagnostics segment, and its common stock has stopped trading on Nasdaq.
Danaher keeps previously communicated Q2 and full-year 2026 guidance ranges, excluding Masimo. The company does not expect a material Masimo contribution in Q2 2026 and plans to update full-year 2026 guidance with its second-quarter earnings release.
Sirius XM Holdings (NASD: SIRI) will join the S&P MidCap 400, replacing Masimo (NASD: MASI), effective before the market opens on June 11, 2026. Danaher (NYSE: DHR), an S&P 500 and 100 constituent, is acquiring Masimo, with the deal expected to close after final conditions.
On June 11, 2026, Sirius XM will be added to the index as a Communication Services company, while Masimo will be removed from the index’s Health Care sector.
SCIEX, part of Danaher (NYSE:DHR), announced platform-wide upgrades to its accurate mass ZenoTOF line at ASMS 2026. Enhancements center on new SCIEX OS 5.0 software, expanded front-end compatibility, and collaborations across leading proteomics and metabolomics software platforms.
SCIEX OS 5.0 adds Central Metrics Tracker, Central Monitoring, Reporter Template Creator, and AI-enabled “helpme” and Calculated Columns. ZT Scan DIA 3.0, Echo MS+ integration, HDX-MS automation, new source options, and partnerships with PEAKS, MS-Dial, and mzmine aim to streamline omics workflows.
SCIEX (NYSE:DHR) launched the novus V55 triple quadrupole mass spectrometer at ASMS, paired with SCIEX OS 5.0 and new AI tools. The system targets high-throughput labs across food, pesticide, pharmaceutical impurity, bioanalysis and PFAS testing.
Key features include aeMRM acquisition up to 1,000 MRMs/second, a 35% smaller footprint, and about 40% lower energy and cooling needs versus the SCIEX 5500+ system, plus centralized monitoring, reporting and AI-enabled workflow support.
Henry Schein (Nasdaq: HSIC) elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus.
Daniel brings decades of healthcare and industrial leadership, including 14 years as Executive Vice President at Danaher (NYSE: DHR) overseeing multiple segments, such as its dental portfolio, and board service at Envista (NYSE: NVST). Company leadership highlighted his understanding of Henry Schein’s business and markets as important for advancing its long-term strategy and integrated healthcare solutions platform.